Studies have found that in breast cancer cells, the AhR agonist Aminoflavone pro-drug (AFP464) can inhibit the formation of breast tumor spheres and suppress TIC growth by inhibiting ITGA6 expression in breast cancer (Brantley et al., 2016). Here, ITGA6 is linked to breast neoplasm.